Insmed | INSM - Capital Social Ordinario

Precio De Mercado
135.17
Cambio Diario
-8.66 -6.02%
Mensual
-8.86%
Anual
93.96%
Q2 Expectativa
132.28




Capital Social Ordinario Cambio Fecha
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Cytokinetics USD 122.26M 145K 2025-12
DBV Technologies USD 136.82M 51.98K 2025-09
Gilead Sciences USD 1.24B 1000K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Novartis USD 1.91B 10.64M 2025-12
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Sarepta Therapeutics USD 104.96M 196K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Vertex Pharmaceuticals USD 254M 0 2025-12